Deadline Extended to August 24, 2017! Submit your proposal today

There's still time to submit your proposal for the "Make Your Medical Device Pitch for Kids!" competition. Deadline extended to Thursday, August 24, 2017 at midnight PDT.

Up to six prizes totaling $250,000 will be awarded to the winning presentations at the nation's leading pediatric innovation symposium on Sunday, September 24, 2017. Are you registered for the Symposium?

Join us for the 5th Annual Pediatric Device Innovation Symposium in San Jose, CA - one day before The MedTech Conference powered by AdvaMed.

It's a results-driven day that brings together medical device innovators, investors, researchers, clinicians, and policy makers to stimulate pediatric device innovation and bring solutions to market faster for the benefit of children everywhere.


Innovation is a principal driver of U.S. economic growth. In 2016, the U.S. spent an estimated $514 billion on research and development — more than any other country in the world — helping the nation rank No. 4 on the Global Innovation Index. According to the results of the ranking, knowledge and technology outputs are America’s particular strengths.

But certain states are due more credit than others for America’s dominance in the tech era. These states continue to foster innovation through investments in education, research and business creation, especially in highly specialized industries.


Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced, following a four-day bench trial, that the United States District Court for the District of New Jersey ruled that TWi Pharmaceuticals, Inc. and its subsidiary infringed U.S. Patent Nos. 7,722,898, 7,910,131, and 8,821,930 by submitting to the FDA an Abbreviated New Drug Application (ANDA) seeking permission to market a generic version of Oxtellar XR® before the expiration of Supernus' patents.  The District Court ruling also confirmed the validity of U.S. Patent Nos. 7,722,898, 7,910,131, and 8,821,930.


The National Institute of Standards and Technology on Wednesday published new guidance on how to strengthen passwords. Why now? Research shows that the de facto standard practice of requiring users to include a mix of uppercase and lowercase letters, numbers and at least one symbol, is more trouble than it’s worth.

“Analyses of breached password databases reveal that the benefit of such rules is not nearly as significant as initially thought,” NIST explained. “The impact on usability and memorability is severe.”


Senseonics Holdings, Inc. (NYSE MKT: SENS), a medical technology company focused on the development and commercialization of Eversense®, a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today announced the pricing of its previously announced underwritten public offering. Senseonics is offering 11,637,500 shares of its common stock, par value $0.001 per share, at a price to the public of $2.15 per share. In connection with the offering, Senseonics has also granted the underwriter a 30-day option to purchase up to an additional 1,745,625 shares of common stock offered in the public offering to cover over-allotments, if any. Senseonics intends to use the net proceeds from the offering primarily to begin commercialization of Eversense in the United States, if approved, to fund continued research and development of future configurations of Eversense, and for working capital and general corporate purposes. The offering is expected to close on August 23, 2017, subject to the satisfaction or waiver of customary closing conditions.


Venture capital spending continues to lag behind the record activity of recent years, but startups needn't worry; industry analysts say there's still billions in dealmaking still to be done.

Nationally, VC firms invested roughly $38 billion in startups and other early-stage companies during the first two quarters this year, down 10 percent from the $42 billion recorded during the same span in 2016 and off about $2 billion from 2015, according to data collected by Pitchbook and the National Venture Capital Association.

Wednesday, August 23, 2017 5:30 p.m. – 8:00 p.m. EST - Summer House Santa Monica, 11825 Grand Park Ave. North Bethesda, MD, 20852

Please join us for our end of summer networking happy hour. It is an opportunity to catch up with old friends and meet new ones. One of the core philosophies of Women In Bio is “women helping women” – it’s a lot easier to help each other when we meet in person! We will provide several opportunities to mix it up and make the most of our time together but the networking won’t be formally structured. We are happy to take suggestions at This email address is being protected from spambots. You need JavaScript enabled to view it..


The Maryland Technology Enterprise Institute (Mtech) at the University of Maryland, College Park seeks an organized, energetic person to assist with operational functions and related activities for the Entrepreneurship and Innovation Program in the Honors College.

This nationally award-winning program helps to develop the entrepreneurial mindsets, skill sets, and resources for first and second-year students. The position-holder would provide coordination and support for: 1.) program operations and administration; 2.) courses and curriculum; 3.) student activities and engagement; 4.) marketing and recruiting; and 5.) development and grants.

This is an exciting opportunity for a self-starting, highly motivated, tech-savvy individual with experience in or desire to engage in an entrepreneurial and/or higher education environment. The ideal candidate will possess a Bachelor's degree along with excellent skills in verbal, written and interpersonal communication, teamwork, multi-tasking, problem-solving, event management, and customer service.

This is a 6-month, hourly, contractual position, up to 40 hours per week, that would begin immediately. To apply, please send a resume and cover letter to This email address is being protected from spambots. You need JavaScript enabled to view it.. For best consideration, please apply by August 28, 2017.


Netherlands-based biotechnology firm MIMETAS has partnered with Roche to develop a new organ-on-a-chip system to support intestinal permeability assessment.

The new system is designed to enable evaluation in perfused three-dimensional (3D) gut tubules in high throughput under exposure to pharmacological compounds. As part of their research, the firms are reported to have grown more than 350 gut tubules under flow to form leak-tight structures.


Altimmune, a drug company based in Gaithersburg, has agreements with investors to raise about $14.7 million, excluding fees and expenses, in a second round of financing. The company plans to sell 15,565 shares of convertible preferred stock and warrants to new and existing investors in a round that the company expects to close around Aug. 21.